Inovio Pharmaceuticals Inc (INO stock) was on its way to the moon early last month until noted market manipulator Andrew Left came out with his hit piece on the stock. INO stock dropped from $19 to $5 on the news and Left made a killing on his shorts. Luckily, our subscribers and readers had us assess the situation and we said to ignore Citron and Andrew Left. As a result, many bought took our advice and bought the dip. We said at the time:
Until the coronavirus pandemic is over, investors will continue to pile into coronavirus stocks. One of the best plays right now for investors is NASDAQ:INO. Dips are to be bought as we still haven’t witnessed peak coronavirus panic. Look for new highs in NASDAQ:INO!
We still believe new highs are coming for INO stock. The fact remains that the coronavirus continues to proliferate. Many are worried we will see another major outbreak in the fall. A vaccine is desperately needed. While we can’t say for certain that NASDAQ:INO will be the first to come to market with a vaccine, it has as good, if not better, chance than other coronavirus stocks. As we take a deeper look, we see a massive short squeeze coming to send INO stock to new highs above $19.
About INO Stock
Inovio Pharmaceuticals Inc (NASDAQ: INO) partnered with Beijing Advaccine Biotechnology Co. to advance the development of INO-4800 which is their version of the vaccine to target COVID-19. Through their partner they hope to quickly advance the vaccine through Chinese clinical trials. They are also developing a vaccine to treat the MERS strain of coronavirus. The company is also developing a phase 3 candidate for cervical HSIL using its compound VGX-3100.
What’s most exciting about NASDAQ:INO is who the company has worked with. It’s the who’s who in the vaccine world. Partners and collaborators include ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute.
$6.9 Million Funding Grant
Last week, The International Vaccine Institute (IVI) announced that the Coalition for Epidemic Preparedness Innovations (CEPI) granted $6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the Korea National Institute of Health (KNIH) for a Phase 1/2 clinical trial of INOVIO’s COVID-19 vaccine candidate (INO-4800) in South Korea. IVI will conduct the trial in parallel to INOVIO’s Phase 1 INO-4800 study currently underway in the US since April 6, 2020 with 40 healthy adults receiving the vaccine candidate and eventually expanding to older adults.
The significance of this cannot be overstated. This is happening in South Korea where they have done a better job than any other country in tracking, tracing, and controlling COVID-19. The fact that South Korea is banking and funding Inovio’s vaccine candidate is huge news. Dr. Jerome H. Kim, Director General of IVI, said:
“Developing a safe and effective COVID-19 vaccine is a global imperative, and we’re pleased to partner with IVI and KNIH to test INO-4800 in South Korea. Our DNA vaccine platform was one of the first technologies to receive support from CEPI to accelerate a COVID-19 vaccine, and IVI conducting safety and efficacy trials in South Korea is a crucial step forward in evaluating this vaccine.”
Bill Gates and INO stock
The biggest endorsement a tiny biotech can get is from Bill Gates. NASDAQ:INO received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA vaccine for COVID-19. Obviously, Bill Gates isn’t paying any attention to Andrew Left and investors shouldn’t as well. Who would you rather invest alongside of – Bill Gates or Andrew Left? We’ll take Bill Gates any day. He can buy and sell Andrew Left thousands of times over and over.
Right now, it’s a mad dash among coronavirus biotech plays to deliver a vaccine. The market is desperate for a solution to the COVID-19 pandemic. Investors are driving up COVID-19 developers amid a mad dash to launch studies to generate preliminary safety and immunogenicity data. The first to do so will, undoubtedly, see a healthy jump in share price. Right now, INO stock is one of the best bets for investors. Bill Gates thinks so and we do too.
Good luck to all (except Andrew Left)!
We will be updating our subscribers on the latest coronavirus stock plays. Sign up today!
Disclosure: We have NO position in NASDAQ:INO and have NOT been compensated for this article. We may or may not initiate a LONG position after 72 hours of publication.